Celyad announces agreement for Horizon Discovery’s shRNA platform to develop next- gen allogeneic CAR-T therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Celyad announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA technology to generate Celyad’s second non-gene- edited allogeneic platform.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login